• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Arms Pharmaceutical touts oral spray for upper respiratory tract infections

February 8, 2017 By Sarah Faulkner

Arms PharmaceuticalArms Pharmaceutical touts oral spray for upper respiratory tract infections touted data from a proof-of-concept clinical trial evaluating its oral spray formulation, Arms-I, for upper respiratory tract infections.

The placebo-controlled trial demonstrated that the oral spray formulation is safe, well-tolerated and reduced influenza symptoms, according to the Cleveland-based pharmaceutical company.

“The results confirm that our Arms-I technology has tremendous potential to lead the next generation of drugs in not only the prevention of many upper respiratory infectious diseases, such as influenza, rhinovirus and respiratory syncytial virus, but in the treatment of them as well,” chief scientific officer Mahmoud Ghannoum said in prepared remarks.

The company’s Arms-I formulation is composed of a broad-spectrum antimicrobial, centylpyridinium chloride, and glycerin and xantham gum, which forms a barrier on the host mucosa. The barrier prevents viral contact and invasion into the host cells.

The FDA has approved the company’s Investigational New Drug Application for a pharmacokinetic trial of its Arms-I drug, Arms Pharmaceutical reported.

“It is an exciting time for the company as we actively begin discussions with potential strategic partners to bring Arms-I to market, a drug with the potential to help millions of people prevent influenza without the worries of side effects or viral resistance,” CEO Afif Ghannoum added.

Filed Under: Clinical Trials, Featured, Respiratory, Wall Street Beat Tagged With: Arms Pharmaceutical

IN CASE YOU MISSED IT

  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement
  • Insulet earnings trounce Q3 estimates as it narrows guidance

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS